Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01383057 · ClinicalTrials.gov registry record · Phase 4
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
A Phase 4 study of Cataracts, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT01383057 is a Phase 4 study of Cataracts that has completed, run by Innovative Medical. The registered enrollment target is 29 participants, below the 94-participant average among 8 other Cataracts trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01383057, a Phase 4 study of Cataracts, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to prove the efficacy and safety of the Femtosecond laser to create a clear corneal incision during cataract surgery.
Conditions Studied
Interventions
- PROCEDURE Femtosecond Laser
Study Locations (1)
Tennessee
- Loden Vision Centers - Goodlettsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01383057
The ClinicalTrials.gov registry entry for NCT01383057 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 8 other Cataracts trials with a reported enrollment target (69% lower). The listed sponsor is Innovative Medical, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 1 intervention - of which Femtosecond Laser is the first listed.
NCT01383057 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01383057 about?
NCT01383057 is a clinical study titled "Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery". The purpose of this study is to prove the efficacy and safety of the Femtosecond laser to create a clear corneal incision during cataract surgery.
What is the current status of trial NCT01383057?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2011-06. Estimated completion is 2012-02.
What conditions does trial NCT01383057 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT01383057?
The interventions under investigation include: Femtosecond Laser (PROCEDURE).
Who is sponsoring clinical trial NCT01383057?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01383057 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
COMPLETED · Phase 4
-
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
COMPLETED · Phase 4
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.